A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant.
Chem Commun (Camb)
; 57(4): 504-507, 2021 Jan 14.
Article
in English
| MEDLINE | ID: covidwho-983835
ABSTRACT
A novel STING agonist, CDGSF, ipsilaterally modified with phosphorothioate and fluorine, was synthesized. The phosphorothioate in CDGSF might be a site for covalent conjugation. Injection of CDGSF generated an immunogenic ("hot") tumor microenvironment to suppress melanoma, more efficiently than dithio CDG. In particular, immunization with SARS-CoV-2 spike protein using CDGSF as an adjuvant elicited an exceptionally high antibody titer and a robust T cell response, overcoming the drawbacks of aluminum hydroxide. These results highlighted the therapeutic potential of CDGSF for cancer immunotherapy and the adjuvant potential of the STING agonist in the SARS-CoV-2 vaccine for the first time.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Skin Neoplasms
/
Melanoma, Experimental
/
Adjuvants, Immunologic
/
COVID-19 Vaccines
/
COVID-19
/
Membrane Proteins
/
Nucleotides, Cyclic
Type of study:
Prognostic study
Topics:
Vaccines
Language:
English
Journal:
Chem Commun (Camb)
Journal subject:
Chemistry
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS